Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GOVX 
GeoVax Labs Inc (GOVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: GOVX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.38
1 Year Target Price $10.38
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.36% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.51M USD | Price to earnings Ratio - | 1Y Target Price 10.38 |
Price to earnings Ratio - | 1Y Target Price 10.38 | ||
Volume (30-day avg) 4 | Beta 3.31 | 52 Weeks Range 0.43 - 3.88 | Updated Date 10/13/2025 |
52 Weeks Range 0.43 - 3.88 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -635.81% |
Management Effectiveness
Return on Assets (TTM) -331.15% | Return on Equity (TTM) -9690.24% |
Valuation
Trailing PE - | Forward PE 10.63 | Enterprise Value 15067054 | Price to Sales(TTM) 2.69 |
Enterprise Value 15067054 | Price to Sales(TTM) 2.69 | ||
Enterprise Value to Revenue 2.45 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 29705360 | Shares Floating 20710926 |
Shares Outstanding 29705360 | Shares Floating 20710926 | ||
Percent Insiders 5.18 | Percent Institutions 10.87 |
Upturn AI SWOT
GeoVax Labs Inc
Company Overview
History and Background
GeoVax Labs Inc. was founded in 2001. It is a biotechnology company focused on developing human vaccines. Key milestones include the development of its Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vaccine platform and clinical trials for HIV, cancer, and infectious diseases.
Core Business Areas
- Vaccine Development: Development and commercialization of vaccines using the MVA-VLP platform, targeting HIV, cancer, and other infectious diseases.
- Licensing and Partnerships: Out-licensing of vaccine technology and collaborations with other pharmaceutical and biotechnology companies.
Leadership and Structure
David Dodd is the Chairman & CEO. The organizational structure is typical of a biotech company, with departments for research, development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- GV-NH6 HIV Vaccine: A preventative HIV vaccine in clinical development. There is no current market share but the HIV vaccine market is substantial. Competitors include Moderna, and Janssen.
- GEO-CM04S1 COVID-19 Vaccine: A COVID-19 vaccine in clinical development. Market share is currently 0. Competitors include Pfizer and Moderna.
- GEO-VAC001A-GO Adjuvant: Investigational vaccine candidate for multiple cancers based on the companyu2019s MVA-VLP platform. Market share is 0. Competitors include Bristol Myers Squibb, Merck, and Roche.
Market Dynamics
Industry Overview
The vaccine market is growing due to increasing awareness of preventative healthcare, aging populations, and emerging infectious diseases. The cancer vaccine market is also expanding with advancements in immuno-oncology.
Positioning
GeoVax Labs Inc. focuses on developing vaccines using its proprietary MVA-VLP platform. Competitive advantages include its platform's safety profile and ability to generate strong immune responses.
Total Addressable Market (TAM)
The global vaccine market is projected to reach hundreds of billions USD. The HIV vaccine market itself is projected to be billions. GeoVax is a relatively small player aiming to capture a portion through successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary MVA-VLP vaccine platform
- Strong preclinical and clinical data
- Experienced management team
- Collaborations with leading research institutions
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- No currently marketed products
- High R&D expenses
Opportunities
- Partnerships with larger pharmaceutical companies
- Government funding for vaccine development
- Expansion into new vaccine targets
- Advancements in vaccine technology
Threats
- Competition from established vaccine manufacturers
- Clinical trial failures
- Regulatory hurdles
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- JNJ
Competitive Landscape
GeoVax competes with larger, more established pharmaceutical companies. Its advantages include its proprietary MVA-VLP platform and focus on unmet medical needs. Its disadvantages include limited resources and dependence on clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancements in its vaccine pipeline and strategic partnerships.
Future Projections: Future growth depends on successful clinical trials and commercialization of its vaccines. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing its HIV vaccine candidate and developing vaccines for other infectious diseases and cancer.
Summary
GeoVax Labs is a clinical-stage biotech company with a promising vaccine platform. Its success depends on positive clinical trial outcomes and strategic partnerships. The company faces significant competition and financial constraints. Future growth hinges on effectively navigating the regulatory landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- GeoVax Labs Inc. website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GeoVax Labs Inc
Exchange NASDAQ | Headquaters Smyrna, GA, United States | ||
IPO Launch date 1999-04-09 | Chairman, President & CEO Mr. David Alan Dodd | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.geovax.com |
Full time employees 17 | Website https://www.geovax.com | ||
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.